<DOC>
	<DOC>NCT01232894</DOC>
	<brief_summary>In this 12-week study, patients were randomized to either open-label indacaterol or standard of care for Chronic Obstructive Pulmonary Disease (COPD) treatment; efficacy and safety were assessed.</brief_summary>
	<brief_title>12-week Open-label Evaluation of Efficacy and Safety of Indacaterol</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) (moderatetosevere as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2007) and: Postbronchodilator forced expiratory volume in 1 second (FEV1) &lt;80% and ≥30% of the predicted normal value Postbronchodilator FEV1/FVC (Forced Vital Capacity) &lt;70% Current COPD bronchodilator treatment that includes a LABA bronchodilator or a fixed dose combination of LABA and Inhaled Corticosteroid (ICS) Patients with a history of asthma Patients who are currently being treated for COPD with tiotropium (Spiriva®) Patients with diabetes Type I or uncontrolled diabetes Type II Patients with a history of certain cardiovascular comorbid conditions Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>indacaterol</keyword>
	<keyword>COPD</keyword>
	<keyword>Long-acting beta2-agonist (LABA)</keyword>
</DOC>